The management of adult growth hormone deficiency syndrome

Bibliography

• Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18(8):901-3
   PubMed Web of Science ®Google Scholar
• Buchanan CR, Preece MA, Milner RD. Mortality, et al. disease in patients treated with human pituitary growth hormone in the United Kingdom [see comments]. BMJ 1991;302(6780):824-8
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357(9254):425-31
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8
   PubMed Web of Science ®Google Scholar
• Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone (GH) on body composition and metabolism in adults with GH deficiency. N Engl J Med 1989;321:1797-803
   PubMed Web of Science ®Google Scholar
• Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221-5
   PubMed Web of Science ®Google Scholar
• Binnerts A, Swart GR, Wilson JH, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol Oxf 1992;37:79-87
   PubMed Web of Science ®Google Scholar
• Whitehead HM, Boreham C, McIlrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol Oxf 1992;36:45-52
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-17
   PubMed Web of Science ®Google Scholar
• Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86(5):1868-70
   PubMed Web of Science ®Google Scholar
• Van den BG, Veldhuis JD, Frolich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996;81(7):2460-7
   PubMed Web of Science ®Google Scholar
• Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002;23(4):431-2
   PubMed Web of Science ®Google Scholar
• Dattani MT, Hindmarsh PC, Brook CG. Inhibition of growth hormone bioactivity by recombinant human growth hormone-binding protein in the eluted stain assay system. J Endocrinol 1994;140(3):445-53
   PubMedGoogle Scholar
• Moseley CT, Phillips JA III. Pituitary gene mutations and the growth hormone pathway. Semin Reprod Med 2000;18(1):21-9
   PubMedGoogle Scholar
• Wajnrajch MP, Gertner JM, Harbison MD, et al. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 1996;12(1):88-90
   PubMedGoogle Scholar
• Dattani MT. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter? Clin Endocrinol (Oxf) 2005;63(2):121-30
   PubMed Web of Science ®Google Scholar
• Gleeson HK, Gattamaneni HR, Smethurst L, et al. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J Clin Endocrinol Metab 2004;89(2):662-6
   PubMed Web of Science ®Google Scholar
• Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989;70(262):145-60
   PubMedGoogle Scholar
• Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81(3):457-62
   PubMed Web of Science ®Google Scholar
• Feigl GC, Bonelli CM, Berghold A, Mokry M. Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 2002;97(5 Suppl):415-21
   PubMed Web of Science ®Google Scholar
• Webb SM, Rigla M, Wagner A, et al. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 1999;84(10):3696-700
   PubMed Web of Science ®Google Scholar
• Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1986;62(6):1173-9
   PubMed Web of Science ®Google Scholar
• Arafah BM, Kailani SH, Nekl KE, et al. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab 1994;79(2):348-54
   PubMed Web of Science ®Google Scholar
• Agha A, Rogers B, Sherlock M, et al. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab 2004;89(10):4929-36
   PubMed Web of Science ®Google Scholar
• Leal-Cerro A, Flores JM, Rincon M, et al. Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury. Clin Endocrinol (Oxf) 2005;62(5):525-32
   PubMed Web of Science ®Google Scholar
• Aimaretti G, Ambrosio MR, Di SC, et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) 2004;61(3):320-6
   PubMed Web of Science ®Google Scholar
• Aimaretti G, Ambrosio MR, Di SC, et al. Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab 2005;90(11):6085-92
   PubMed Web of Science ®Google Scholar
• Clayton PE, Price DA, Shalet SM. Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 1987;62(3):222-6
   PubMedGoogle Scholar
• Cacciari E, Tassoni P, Parisi G, et al. Pitfalls in diagnosing impaired growth hormone (GH) secretion: retesting after replacement therapy of 63 patients defined as GH deficient. J Clin Endocrinol Metab 1992;74(6):1284-9
   PubMedGoogle Scholar
• Wacharasindhu S, Cotterill AM, Camacho-Hubner C, et al. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol (Oxf) 1996;45(5):553-6
   PubMedGoogle Scholar
• Longobardi S, Merola B, Pivonello R, et al. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab 1996;81(3):1244-7
   PubMedGoogle Scholar
• Nicolson A, Toogood AA, Rahim A, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood [see comment]. Clin Endocrinol (Oxf) 1996;44(3):311-6
   PubMed Web of Science ®Google Scholar
• Tauber M, Moulin P, Pienkowski C, et al. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997;82(2):352-6
   PubMedGoogle Scholar
• Vahl N, Jorgensen JO, Jurik AG, Christiansen JS. Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab 1996;81(6):2209-15
   PubMedGoogle Scholar
• Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998;83(5):1615-8
   PubMed Web of Science ®Google Scholar
• Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87(5):2067-79
   PubMed Web of Science ®Google Scholar
• Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157(6):695-700
   PubMed Web of Science ®Google Scholar
• Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83(2):379-81
   PubMed Web of Science ®Google Scholar
• Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;87(2):477-85
   PubMed Web of Science ®Google Scholar
• Toogood AA, Beardwell CG, Shalet SM. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol (Oxf) 1994;41(4):511-6
   PubMed Web of Science ®Google Scholar
• Clayton PE, Cuneo RC, Juul A, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152(2):165-70
   PubMed Web of Science ®Google Scholar
• Hoffman DM, O'Sullivan AJ, Freund J, Ho KK. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab 1995;80(1):72-7
   PubMed Web of Science ®Google Scholar
• Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995;42(2):179-89
   PubMedGoogle Scholar
• Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000;85(10):3762-9
   PubMed Web of Science ®Google Scholar
• Jorgensen JOL, Thuesen L, Muller J, et al. Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994;130:224-28
   PubMed Web of Science ®Google Scholar
• Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89(5):2048-56
   PubMed Web of Science ®Google Scholar
• Svensson J, Sunnerhagen KS, Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 2003;88(5):2061-9
   PubMed Web of Science ®Google Scholar
• Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991;70(2):688-94
   PubMed Web of Science ®Google Scholar
• Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999;84(1):279-84
   PubMed Web of Science ®Google Scholar
• Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991;70(2):695-700
   PubMed Web of Science ®Google Scholar
• Juul A, Behrenscheer A, Tims T, et al. Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise. Clin Endocrinol Oxf 1993;38:237-44
   PubMedGoogle Scholar
• Koranyi J, Svensson J, Gotherstrom G, et al. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J Clin Endocrinol Metab 2001;86(10):4693-9
   PubMed Web of Science ®Google Scholar
• Bottinelli R, Narici M, Pellegrino MA, et al. Contractile properties and fiber type distribution of quadriceps muscles in adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997;82(12):4133-8
   PubMedGoogle Scholar
• Gotherstrom G, Bengtsson BA, Bosaeus I, et al. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007;92(4):1442-5
   PubMed Web of Science ®Google Scholar
• Gibney J, Wallace JD, Spinks T, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999;84(8):2596-602
   PubMed Web of Science ®Google Scholar
• Burman P, Johansson AG, Siegbahn A, et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82(2):550-5
   PubMed Web of Science ®Google Scholar
• Drake WM, Coyte D, Camacho-Hubner C, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83(11):3913-19
   PubMed Web of Science ®Google Scholar
• Bosaeus I, Johannsson G, Rosen T, et al. Comparison of methods to estimate body fat in growth hormone deficient adults. Clin Endocrinol (Oxf) 1996;44(4):395-402
   PubMedGoogle Scholar
• Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78(3):669-74
   PubMed Web of Science ®Google Scholar
• Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004;89(3):1124-30
   PubMedGoogle Scholar
• Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137(3):240-5
   PubMed Web of Science ®Google Scholar
• Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16(2):398-405
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jorgensen JO, Hagen C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas – a case-control study. Clin Endocrinol (Oxf) 2002;56(2):159-67
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006;21(4):520-8
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Bengtsson BA, Isaksson OG, et al. Growth hormone and bone. Endocr Rev 1998;19(1):55-79
   PubMed Web of Science ®Google Scholar
• Johansson AG, Burman P, Westermark K, Ljunghall S. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 1992;23(2):447-52
   Google Scholar
• Johansson AG, Lindh E, Blum WF, et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996;81(1):44-8
   PubMed Web of Science ®Google Scholar
• Bravenboer N, Holzmann P, de BH, et al. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996;18(6):551-7
   PubMedGoogle Scholar
• Bravenboer N, Holzmann PJ, ter Maaten JC, et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 2005;20(10):1778-84
   PubMed Web of Science ®Google Scholar
• Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996;81(9):3352-9
   PubMedGoogle Scholar
• Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88(9):4124-9
   PubMed Web of Science ®Google Scholar
• Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125(11):883-90
   PubMed Web of Science ®Google Scholar
• Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997;82(1):82-8
   PubMed Web of Science ®Google Scholar
• Bolotin HH, Sievanen H, Grashuis JL. Patient-specific DXA bone mineral density inaccuracies: quantitative effects of nonuniform extraosseous fat distributions. J Bone Miner Res 2003;18(6):1020-7
   PubMedGoogle Scholar
• Gotherstrom G, Bengtsson BA, Bosaeus I, et al. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 2007;156(1):55-64
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Hamdy NA, Pereira AM, et al. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf) 2004;60(5):568-75
   PubMed Web of Science ®Google Scholar
• Johannsson G, Rosen T, Bosaeus I, et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81(8):2865-73
   PubMed Web of Science ®Google Scholar
• Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf) 2001;54(4):525-32
   PubMedGoogle Scholar
• Hyer SL, Rodin DA, Tobias JH, et al. Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child 1992;67:1472-4
   PubMed Web of Science ®Google Scholar
• Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol 2003;41(3):228-34
   PubMedGoogle Scholar
• Teegarden D, Proulx WR, Martin BR, et al. Peak bone mass in young women. J Bone Miner Res 1995;10(5):711-5; 2
   PubMedGoogle Scholar
• Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab 2003;16(Suppl 2):327-35
   PubMedGoogle Scholar
• Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 2004;60(2):175-84
   PubMedGoogle Scholar
• Drake WM, Carroll PV, Maher KT, et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003;88(4):1658-63
   PubMedGoogle Scholar
• Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003;88(11):5273-80
   PubMed Web of Science ®Google Scholar
• Mauras N, Pescovitz OH, Allada V, et al. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a Phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90(7):3946-55
   PubMed Web of Science ®Google Scholar
• Christ ER, Cummings MH, Jackson N, et al. Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study. J Clin Endocrinol Metab 2004;89(4):1801-7
   PubMedGoogle Scholar
• Christ ER, Cummings MH, Albany E, et al. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab 1999;84(1):307-16
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Abs R, Bennmarker H, et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999;84(11):3929-35
   PubMed Web of Science ®Google Scholar
• Attanasio AF, Bates PC, Ho KK, et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status – 3-year results from the HypoCCS Database. J Clin Endocrinol Metab 2002;87(4):1600-6
   PubMedGoogle Scholar
• Maison P, Griffin S, Nicoue-Beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004;89(5):2192-9
   PubMed Web of Science ®Google Scholar
• Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997;82(1):82-8
   PubMed Web of Science ®Google Scholar
• Colao A, Di SC, Salerno M, et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87(8):3650-5
   PubMed Web of Science ®Google Scholar
• Kearney T, de Gallegos CN, Proudler A, et al. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects. Metabolism 2003;52(1):50-9
   PubMedGoogle Scholar
• Leonsson M, Hulthe J, Oscarsson J, et al. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 2002;57(6):751-9
   PubMedGoogle Scholar
• Murata M, Kaji H, Mizuno I, et al. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur J Endocrinol 2003;148(3):333-8
   PubMedGoogle Scholar
• Colao A, Di SC, Filippella M, et al. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2004;61(3):360-6
   PubMed Web of Science ®Google Scholar
• Markussis V, Beshyah SA, Fisher C, et al. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur J Endocrinol 1997;136(2):157-64
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128(4):262-9
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Verhovec R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults [see comments]. J Clin Endocrinol Metab 1999;84(2):453-57
   PubMed Web of Science ®Google Scholar
• Borson-Chazot F, Serusclat A, Kalfallah Y, et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999;84(4):1329-33
   PubMed Web of Science ®Google Scholar
• Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2002;56(4):493-501
   PubMed Web of Science ®Google Scholar
• Boger RH, Skamira C, Bode-Boger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996;98(12):2706-13
   PubMed Web of Science ®Google Scholar
• Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clin Endocrinol (Oxf) 2004;60(5):550-9
   PubMedGoogle Scholar
• Colao A, Di SC, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002;87(3):1088-93
   PubMed Web of Science ®Google Scholar
• Jallad RS, Liberman B, Vianna CB, et al. Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res 2003;13(2-3):81-8
   PubMedGoogle Scholar
• Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004;151(Suppl 1):S93-101
   Web of Science ®Google Scholar
• Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003;108(21):2648-52
   PubMed Web of Science ®Google Scholar
• Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endocrinol Oxf 1995;43(2):143-9
   PubMed Web of Science ®Google Scholar
• Thuesen L, Jorgensen JO, Muller JR, et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf) 1994;41(5):615-20
   PubMed Web of Science ®Google Scholar
• Johansson JO, Landin K, Tengborn L, et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 1994;14:434-7
   PubMed Web of Science ®Google Scholar
• Sverrisdottir YB, Elam M, Caidahl K, et al. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 2003;21(10):1905-14
   PubMedGoogle Scholar
• Johansson JO, Landin K, Johannsson G, Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996;76(3):422-8
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000;133(2):111-22
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab 2001;86(4):1518-24
   PubMed Web of Science ®Google Scholar
• Leonsson M, Hulthe J, Johannsson G, et al. Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clin Endocrinol (Oxf) 2003;59(2):242-50
   PubMed Web of Science ®Google Scholar
• Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 2004;113(1):25-7
   PubMed Web of Science ®Google Scholar
• Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996;81(2):555-64
   PubMed Web of Science ®Google Scholar
• Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995;44(9):1126-9
   PubMed Web of Science ®Google Scholar
• al Shoumer KA, Gray R, Anyaoku V, et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 1998;48(6):795-802
   PubMed Web of Science ®Google Scholar
• Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80:153-9
   PubMedGoogle Scholar
• Svensson J, Fowelin J, Landin K, Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002;87(5):2121-7
   PubMed Web of Science ®Google Scholar
• Segerlantz M, Bramnert M, Manhem P, Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults. Eur J Endocrinol 2003;149(6):511-9
   PubMedGoogle Scholar
• Christopher M, Hew FL, Oakley M, et al. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab 1998;83(5):1668-81
   PubMed Web of Science ®Google Scholar
• Jorgensen JOL, Vahl N, Nyholm B. Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults. Endocrinol Metab 1996;3:281-6
   Google Scholar
• Arwert LI, Roos JC, Lips P, et al. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 2005;63(3):310-6
   PubMed Web of Science ®Google Scholar
• Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42(11):1443-7
   PubMed Web of Science ®Google Scholar
• Bramnert M, Segerlantz M, Laurila E, et al. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 2003;88(4):1455-63
   PubMedGoogle Scholar
• Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1(7285):785-9
   PubMed Web of Science ®Google Scholar
• Nielsen S, Moller N, Christiansen JS, Jorgensen JO. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 2001;50(10):2301-8
   PubMed Web of Science ®Google Scholar
• Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81(3):1169-72
   PubMed Web of Science ®Google Scholar
• Erfurth EM, Bulow B, Nordstrom CH, Doubled mortality rate in irradiated patients reoperated for regrowth of a macroadenoma of the pituitary gland. Eur J Endocrinol 2004;150(4):497-502
   PubMedGoogle Scholar
• Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism [see comments]. Clin Endocrinol (Oxf) 1997;46(1):75-81
   PubMed Web of Science ®Google Scholar
• Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000;85(4):1420-5
   PubMed Web of Science ®Google Scholar
• Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46(1):75-81
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959 – 85: a cohort study. Lancet 2002;360(9329):273-7
   PubMed Web of Science ®Google Scholar
• Stochholm K, Gravholt CH, Laursen T, et al. Mortality and GH deficiency: a nationwide study. Eur J Endocrinol 2007;157(1):9-18
   PubMedGoogle Scholar
• Stochholm K, Laursen T, Green A, et al. Morbidity and GH deficiency: a nationwide study. Eur J Endocrinol 2008;158(4):447-57
   PubMedGoogle Scholar
• Svensson J, Bengtsson BA, Rosen T, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004;89(7):3306-12
   PubMed Web of Science ®Google Scholar
• Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004;89(4):1684-93
   PubMed Web of Science ®Google Scholar
• McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989356:70-2; discussion 73-4
   PubMedGoogle Scholar
• Holmes SJ, Shalet SM. Factors influencing the desire for long-term growth hormone replacement in adults. Clin Endocrinol (Oxf) 1995;43(2):151-7
   PubMed Web of Science ®Google Scholar
• Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80(12):3585-90
   PubMed Web of Science ®Google Scholar
• Maard G, Lundin K, Borg G, et al. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1994;1(Suppl A):43-9
   Google Scholar
• Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 1999;51(5):565-73
   PubMed Web of Science ®Google Scholar
• Murray RD, Skillicorn CJ, Howell SJ, Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol (Oxf) 1999;50(6):749-57
   PubMed Web of Science ®Google Scholar
• Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83(9):3184-9
   PubMed Web of Science ®Google Scholar
• Deijen JB, Arwert LI, Witlox J, Drent ML. Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis. Health Qual Life Outcomes 2005;3:63-5
   PubMedGoogle Scholar
• Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 2002;57(3):363-70
   PubMed Web of Science ®Google Scholar
• Wiren L, Bengtsson BA, Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol (Oxf) 1998;48(5):613-20
   PubMedGoogle Scholar
• Arwert LI, Veltman DJ, Deijen JB, et al. Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study. Neuroendocrinology 2006;83(1):12-9
   PubMed Web of Science ®Google Scholar
• Arwert LI, Deijen JB, Witlox J, Drent ML. The influence of growth hormone (GH) substitution on patient-reported outcomes and cognitive functions in GH-deficient patients: a meta-analysis. Growth Horm IGF Res 2005;15(1):47-54
   PubMed Web of Science ®Google Scholar
• Orme SM, Sebastian JP, Oldroyd B, et al. Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy. Clin Endocrinol Oxf 1992;37:453-9
   PubMed Web of Science ®Google Scholar
• Hoffman AR, Strasburger CJ, Zagar A, et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 2004;89(7):3224-33
   PubMed Web of Science ®Google Scholar
• Kehely A, Bates PC, Frewer P, et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002;87(5):1974-9
   PubMed Web of Science ®Google Scholar
• Bryant J, Loveman E, Cave C, Endocrinology trial design: adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adults. J Endocrinol 2002;175(2):545-52
   PubMed Web of Science ®Google Scholar
• Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83(2):382-95
   PubMed Web of Science ®Google Scholar
• Carroll PV, Littlewood R, Weissberger AJ, et al. The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. Eur J Endocrinol 1997;137(2):146-53
   PubMedGoogle Scholar
• Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med 1993;329(9):665-6
   PubMedGoogle Scholar
• Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355(9204):610-3
   PubMed Web of Science ®Google Scholar
• Monson JP, Bengtsson BA, Abs R, et al. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000;355(9216):1728-9
   PubMed Web of Science ®Google Scholar
• Hansen R, Koller EA, Malozowski S. Full remission of growth hormone (GH)-induced retinopathy after GH treatment discontinuation: long-term follow-up. J Clin Endocrinol Metab 2000;85(7):2627
   PubMedGoogle Scholar
• Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38(6):571-8
   PubMed Web of Science ®Google Scholar
• Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995;80(4):1416-22
   PubMedGoogle Scholar
• Hatrick AG, Boghalo P, Bingham JB, et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 2002;146(6):807-11
   PubMed Web of Science ®Google Scholar
• Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001;86(11):5172-5
   PubMedGoogle Scholar
• Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006;64(5):556-60
   PubMedGoogle Scholar
• Jostel A, Mukherjee A, Hulse PA, et al. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 2005;62(6):698-705
   PubMed Web of Science ®Google Scholar
• Fradkin JE, Mills JL, Schonberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993;270(23):2829-32
   PubMedGoogle Scholar
• Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49(4):441-5
   PubMedGoogle Scholar
• Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90(2):800-4
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91(9):3494-8
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87(7):3136-41
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study [see comments]. Science 1998;279(5350):563-6
   PubMed Web of Science ®Google Scholar
• Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18(4):847-53
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer [In Process Citation]. Lancet 1998;351(9113):1393-6
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91(7):620-5
   PubMed Web of Science ®Google Scholar
• Laursen T. Clinical pharmacological aspects of growth hormone administration. Growth Horm IGF Res 2004;14(1):16-44; 1
   PubMedGoogle Scholar
• Johannsson G, Rosen T, Bengtsson BA. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol Oxf 1997;47(5):571-81
   PubMed Web of Science ®Google Scholar
• Murray RD, Skillicorn CJ, Howell SJ, et al. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol (Oxf) 1999;50(6):749-57
   PubMed Web of Science ®Google Scholar
• Murray RD, Shalet SM. Adult growth hormone replacement: lessons learned and future direction. J Clin Endocrinol Metab 2002;87(10):4427-8
   PubMedGoogle Scholar
• Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 1999;84(11):3956-60
   PubMed Web of Science ®Google Scholar
• Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4; therapy become mandatory? J Clin Endocrinol Metab 2002;87(5):2042-5
   PubMed Web of Science ®Google Scholar
• Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 2004;89(11):5397-401
   PubMed Web of Science ®Google Scholar
• Weaver JU, Thaventhiran L, Noonan K, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol Oxf 1994;41(5):639-48
   PubMed Web of Science ®Google Scholar
• Ehrnborg C, Hakkaart-Van RL, Jonsson B, et al. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000;17(6):621-8
   PubMedGoogle Scholar
• Hernberg-Stahl E, Luger A, Abs R, et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001;86(11):5277-81
   PubMed Web of Science ®Google Scholar
• Saller B, Mattsson AF, Kann PH, et al. Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany. Eur J Endocrinol 2006;154(6):843-50
   PubMedGoogle Scholar
• Svensson J, Mattsson A, Rosen T, et al. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res 2004;14(3):207-15
   PubMed Web of Science ®Google Scholar